Trans-Middle-Ear Mucosal Gas Exchange Project 1, Specific Aim 1
NCT ID: NCT01925482
Last Updated: 2019-02-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
16 participants
INTERVENTIONAL
2014-05-13
2015-05-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Gas Supply, Demand and Middle Ear Gas Balance: Specific Aim 3
NCT01925495
Gas Supply, Demand and Middle Ear Gas Balance: Specific Aim 3c
NCT00422851
Gas Supply, Demand and Middle Ear Gas Balance: Specific Aim 2
NCT00694421
A Non-invasive Device to Remove Fluid From the Middle Ear
NCT03978195
Effect of Simethicone on Eustachian Tube Dysfunction
NCT01312038
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
CROSSOVER
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1 -- no history of otitis media
no history of otitis media
6%CO2, 25%O2, balance N2
exposure of middle ear to gas
6% CO2, 0%O2, balance N2
exposure of middle ear to gas
20%CO2, 6%O2, balance N2
exposure of middle ear to gas
0%CO2, 6%O2, balance N2
exposure of middle ear to gas
6% CO2, 6%O2, balance N2
exposure of middle ear to gas
6%CO2, 6%O2, 0%N2, balance argon
exposure of middle ear to gas
Group 2 --patent tympanostomy tube
at least 1 patent tympanostomy tube
6%CO2, 25%O2, balance N2
exposure of middle ear to gas
6% CO2, 0%O2, balance N2
exposure of middle ear to gas
20%CO2, 6%O2, balance N2
exposure of middle ear to gas
0%CO2, 6%O2, balance N2
exposure of middle ear to gas
6% CO2, 6%O2, balance N2
exposure of middle ear to gas
6%CO2, 6%O2, 0%N2, balance argon
exposure of middle ear to gas
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
6%CO2, 25%O2, balance N2
exposure of middle ear to gas
6% CO2, 0%O2, balance N2
exposure of middle ear to gas
20%CO2, 6%O2, balance N2
exposure of middle ear to gas
0%CO2, 6%O2, balance N2
exposure of middle ear to gas
6% CO2, 6%O2, balance N2
exposure of middle ear to gas
6%CO2, 6%O2, 0%N2, balance argon
exposure of middle ear to gas
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No history of significant ME disease; intact tympanic membrane (Group 1 only)
* Functional tympanostomy tube or chronic perforation after tube extruded; tube placed for middle-ear effusion/Eustachian tube dysfunction (Group 2)
* No history of past ME surgeries other than ventilation tubes (Group 2),
* Able to comprehend study risks and provide written Informed Consent
Exclusion Criteria
* Have ME fluid or otitis media (OM)at the time of presentation for ventilation tube insertion (Group 1 only)
* Have drainage through the ventilation tube at the time of testing
* Have a cold or allergic rhinitis at the time of testing
* Taking any prescription drug with the exception of those for birth control
* Have a known or suspected allergy/adverse reaction to any of the study drugs use to prepare the tympanic membrane for ventilation tube insertion (Group 1 only)
* Have a hearing threshold \>15 dB or a \>10 dB air-bone gap at any of the speech frequencies (Group 1 only)
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Cuneyt M. Alper
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cuneyt M. Alper
Professor, Otolaryngology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Cuneyt M Alper, MD
Role: PRINCIPAL_INVESTIGATOR
University of Pittsburgh
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Middle Ear Physiology Laboratory, University of Pittsburgh
Pittsburgh, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRO13050158
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.